Searched for
EMCURE LABORATORIES
IPO Calendar: Primary market gears up for another robust week as 3 companies look to raise Rs 2,700 crApart from the above 3 public offers, the Street will see as many 11 listings including that of Allied Blenders and Vraj Iron and Steel, wh...
Gennova in talks with govt to price mRNA vaccine competitivelySince Gennova has the manufacturing-at-risk approval, it has already produced 7 million doses that have been released not only by the compa...
Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravirIn a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients a...
Emcure to soon file papers for Rs 4,000 crore IPOThe IPO will consist of a primary issue and offer for sale from its promoter Satish Mehta and existing investor Bain Capital which acquired...
MSD to sign licensing pacts with 5 Indian drug firms for oral drug candidate for COVID-19MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufactur...
Generics company Emcure plans Rs 4,000 crore IPOEmcure may appoint as many as six bankers for the IPO including JM Financial, Kotak Capital, Axis Capital and SBI Capital, the people said....
Emcure to launch generic breast cancer medicineEribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients. It costs Rs 5,000 per vial.
Pharma stocks soar despite US lawsuitAmong other listed stocks out of the five, Cadila Healthcare gained 2.87 per cent at Rs 512 at around the same time.
US states sue 5 Indian generic drug makers over price cartelisationThe new lawsuit has also named some individual executives, including Rajiv Malik, president of Mylan, and Satish Mehta, MD of Emcure Pharma.
Alkem Lab approaches SEBI to raise Rs 1,500-3,500 crore via IPOAlkem Laboratories filed draft papers with capital markets regulator Sebi to raise an estimated Rs 1,500-3,500 crore through an IPO.
Shares of Sun Pharma, Ranbaxy rise after regulatory nods for merger dealAt end of trade, Sun Pharmaceutical Industries ended at Rs 1,039.85, up 1.55 per cent and Ranbaxy Laboratories closed at Rs 819.55 apiece, ...
Sun-Ranbaxy $4 billion merger completedSun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.
Sun Pharma gets RBI nod for transfer of Ranbaxy's overseas investmentsThe central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, t...
Sun-Ranbaxy deal gets final CCI nod; Emcure to buy 7 brandsThis clears the way for creating the biggest drug company in India with a market share of 9% and the fifth largest generic drug firm in the...
Pharma MNCs GSK, Merck, Pfizer and others prefer tie-ups over acquisitions with Indian firmsWith Indian drug makers flooding the developed markets, GSK, Merck, Pfizer now prefer tie-ups over acquisitions with Indian players.
- Drug cos eye US entry after FDA checks
The US drug regulator has inspected the manufacturing plants of at least half-a-dozen Indian drugmakers, raising hopes that these companies...
- Centre bans anti-obesity drug due to side effects
The government has banned manufacturing and sale of anti-obesity medicine Sibutramine and its combination drugs sold under various brands d...